CASI Pharma: Bi-1206 Granted Orphan Drug Designation By FDA For Follicular Lymphoma Treatment

CASI Pharmaceuticals Inc. (CASI) said that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its partner BioInvent International AB, for BI-1206, an investigational anti-FcyRllB antibody, for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma or NHL.

In Thursday pre-market trade, CASI was trading at $0.73 up $0.03 or 5.65%.

BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials.

One is evaluating the BI-1206 combination with rituximab for the treatment of Non-Hodgkin lymphoma, which includes patients with follicular lymphoma, MCL and marginal zone lymphoma (MZL) who have relapsed or are refractory to rituximab.

A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT